These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2042 related items for PubMed ID: 31818312

  • 41. Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression.
    Li S, Lu X, Zheng D, Chen W, Li Y, Li F.
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3485-3499. PubMed ID: 35907010
    [Abstract] [Full Text] [Related]

  • 42. The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene.
    Liu S, Li Q, Li G, Zhang Q, Zhuo L, Han X, Zhang M, Chen X, Pan T, Yan L, Jin T, Wang J, Lv Q, Sui X, Xie T.
    Cell Death Dis; 2020 Nov 11; 11(11):969. PubMed ID: 33177491
    [Abstract] [Full Text] [Related]

  • 43. The circular RNA circ-ERBIN promotes growth and metastasis of colorectal cancer by miR-125a-5p and miR-138-5p/4EBP-1 mediated cap-independent HIF-1α translation.
    Chen LY, Wang L, Ren YX, Pang Z, Liu Y, Sun XD, Tu J, Zhi Z, Qin Y, Sun LN, Li JM.
    Mol Cancer; 2020 Nov 23; 19(1):164. PubMed ID: 33225938
    [Abstract] [Full Text] [Related]

  • 44. Long noncoding RNA RP11-757G1.5 sponges miR-139-5p and upregulates YAP1 thereby promoting the proliferation and liver, spleen metastasis of colorectal cancer.
    Zhu X, Bu F, Tan T, Luo Q, Zhu J, Lin K, Huang J, Luo C, Zhu Z.
    J Exp Clin Cancer Res; 2020 Oct 06; 39(1):207. PubMed ID: 33023613
    [Abstract] [Full Text] [Related]

  • 45. m6A-dependent glycolysis enhances colorectal cancer progression.
    Shen C, Xuan B, Yan T, Ma Y, Xu P, Tian X, Zhang X, Cao Y, Ma D, Zhu X, Zhang Y, Fang JY, Chen H, Hong J.
    Mol Cancer; 2020 Apr 03; 19(1):72. PubMed ID: 32245489
    [Abstract] [Full Text] [Related]

  • 46. Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
    Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L, Pan L, Su G.
    J Hematol Oncol; 2023 Feb 22; 16(1):14. PubMed ID: 36814345
    [No Abstract] [Full Text] [Related]

  • 47. LINC01503/miR-342-3p facilitates malignancy in non-small-cell lung cancer cells via regulating LASP1.
    Shen Q, Sun Y, Xu S.
    Respir Res; 2020 Sep 16; 21(1):235. PubMed ID: 32938459
    [Abstract] [Full Text] [Related]

  • 48. Long noncoding RNA HCG18 up-regulates the expression of WIPF1 and YAP/TAZ by inhibiting miR-141-3p in gastric cancer.
    Liu Y, Lin W, Dong Y, Li X, Lin Z, Jia J, Zou W, Pan Y.
    Cancer Med; 2020 Sep 16; 9(18):6752-6765. PubMed ID: 32725768
    [Abstract] [Full Text] [Related]

  • 49. MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA.
    Du M, Zhang Y, Mao Y, Mou J, Zhao J, Xue Q, Wang D, Huang J, Gao S, Gao Y.
    Biochem Biophys Res Commun; 2017 Jan 22; 482(4):582-589. PubMed ID: 27856248
    [Abstract] [Full Text] [Related]

  • 50. Correction to: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
    Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L, Pan L, Su G.
    J Hematol Oncol; 2020 Aug 03; 13(1):106. PubMed ID: 32746876
    [Abstract] [Full Text] [Related]

  • 51. miR-124-3p availability is antagonized by LncRNA-MALAT1 for Slug-induced tumor metastasis in hepatocellular carcinoma.
    Cui RJ, Fan JL, Lin YC, Pan YJ, Liu C, Wan JH, Wang W, Jiang ZY, Zheng XL, Tang JB, Yu XG.
    Cancer Med; 2019 Oct 03; 8(14):6358-6369. PubMed ID: 31466138
    [Abstract] [Full Text] [Related]

  • 52. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D, Guo J, Wu Y, Du J, Wang X, An J, Hu B, Kong L, Di W, Wang W.
    Theranostics; 2019 Oct 03; 9(7):2036-2055. PubMed ID: 31037155
    [Abstract] [Full Text] [Related]

  • 53. MicroRNA-361-3p suppresses tumor cell proliferation and metastasis by directly targeting SH2B1 in NSCLC.
    Chen W, Wang J, Liu S, Wang S, Cheng Y, Zhou W, Duan C, Zhang C.
    J Exp Clin Cancer Res; 2016 May 10; 35():76. PubMed ID: 27164951
    [Abstract] [Full Text] [Related]

  • 54. Long non-coding RNA PICSAR knockdown inhibits the progression of cutaneous squamous cell carcinoma by regulating miR-125b/YAP1 axis.
    Lu X, Gan Q, Gan C, Zheng Y, Cai B, Li X, Li D, Yin G.
    Life Sci; 2021 Jun 01; 274():118303. PubMed ID: 32841663
    [Abstract] [Full Text] [Related]

  • 55. METTL3-mediated m6A modification of circGLIS3 promotes prostate cancer progression and represents a potential target for ARSI therapy.
    Cheng X, Yang H, Chen Y, Zeng Z, Liu Y, Zhou X, Zhang C, Xie A, Wang G.
    Cell Mol Biol Lett; 2024 Aug 14; 29(1):109. PubMed ID: 39143552
    [Abstract] [Full Text] [Related]

  • 56. MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer.
    Liu MX, Zhou KC, Cao Y.
    Mol Cancer; 2014 Nov 06; 13():245. PubMed ID: 25373388
    [Abstract] [Full Text] [Related]

  • 57. Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis.
    Chu D, Li P, Li Y, Shi J, Huang S, Jiao P.
    Thorac Cancer; 2021 Nov 06; 12(21):2894-2906. PubMed ID: 34523261
    [Abstract] [Full Text] [Related]

  • 58. CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p.
    Li M, Wang Q, Zhang X, Yan N, Li X.
    Cell Cycle; 2021 Jul 06; 20(13):1279-1294. PubMed ID: 34097560
    [Abstract] [Full Text] [Related]

  • 59. Long non-coding RNA XIST expedites lung adenocarcinoma progression through upregulating MDM2 expression via binding to miR-363-3p.
    Rong H, Chen B, Wei X, Peng J, Ma K, Duan S, He J.
    Thorac Cancer; 2020 Mar 06; 11(3):659-671. PubMed ID: 31968395
    [Abstract] [Full Text] [Related]

  • 60. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L, Xu J, Zhao F, Dai X, Tao J, Pan J, Shi A, Shen Z, Su C, Zhang Y.
    Eur J Pharmacol; 2021 May 15; 899():174054. PubMed ID: 33771522
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 103.